<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Oxidation processes play an important role in atherogenesis </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin IXalpha</z:chebi> is recognised as a potent <z:chebi fb="11" ids="22586">antioxidant</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we assessed the role of elevated serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels in the prevention of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The occurrence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> was determined in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e> (GS) patients above 40 years (n=50) </plain></SENT>
<SENT sid="4" pm="."><plain>The diagnosis was based on past medical history and ECG criteria </plain></SENT>
<SENT sid="5" pm="."><plain>The occurrence was related to that of the comparable general population (n=2296) </plain></SENT>
<SENT sid="6" pm="."><plain>Serum biochemistry, including the total <z:chebi fb="11" ids="22586">antioxidant</z:chebi> status was evaluated in the GS subjects, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> patients (n=38) and control subjects (n=38) </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The prevalence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> in GS subjects (aged 49.7+/-9.0 years) was 2% (0.05-10.7%, 95% confidence interval), compared to 12.1% in a general population (P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin</z:chebi>, total <z:chebi fb="11" ids="22586">antioxidant</z:chebi> capacity and <z:chebi fb="6" ids="39025">high density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) cholesterol were found to be significantly higher in GS subjects compared to control groups (P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>According to linear discriminant analysis, <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> rather than elevation of <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels seemed to be more important in protection from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In the present study, low prevalence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> in GS subjects was detected </plain></SENT>
<SENT sid="11" pm="."><plain>It may be presumed that <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> prevent the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> by increasing the serum <z:chebi fb="11" ids="22586">antioxidant</z:chebi> capacity </plain></SENT>
</text></document>